2 Key Reasons Thursday's Stock Market Was Encouraging

2 Key Reasons Thursday's Stock Market Was Encouraging

We would also note the markets appear to be well undervalued via the 'rule of 20' theory.

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

Slogging Through the Deep-Value Valley With Valhi and NL Industries in Tow

Shares of the related companies are struggling, which can be the norm for investments in out-of-favor businesses.

Ulta Beauty Is Slipping After Issuing Weak Fourth-Quarter Outlook

Ulta Beauty Is Slipping After Issuing Weak Fourth-Quarter Outlook

Ulta shares are getting hit after the beauty store chain issued a weak outlook for its fourth quarter.

Yum! Brands Is Showing All the Right Signals - Trade From the Long Side

Yum! Brands Is Showing All the Right Signals - Trade From the Long Side

Let's check out the charts and indicators.

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

Former Allies Align Against Facebook as its Very Public Problems Persist

Former Allies Align Against Facebook as its Very Public Problems Persist

The stench wafting off of the heap of bad news and the myriad of issues confronting FB has driven many former friends, including major investors, away.

Here's an Opportunity With Ulta Stock

Here's an Opportunity With Ulta Stock

Honestly, the name is still expensive in my opinion, but a couple of items stand out.

Gene Editing Offers Promise of Personalized Health Care -- Here's How to Play It

Gene Editing Offers Promise of Personalized Health Care -- Here's How to Play It

CRISPR is a gene-editing technique that uses molecular scissors to precisely snip genetic code. With it, researchers have modified genes to help blind people see, cure sickle cell disease in some patients and speed up the development of numerous new drug treatments.

Why Procter & Gamble, Coca-Cola, Pepsico Could Belong in Your 2019 Portfolio

Why Procter & Gamble, Coca-Cola, Pepsico Could Belong in Your 2019 Portfolio

These three companies have something in common, which a disciplined investor should consider going into 2019.

Facebook, Not Liked of Late, Could Stage a Technical Rally Into Year-End

Facebook, Not Liked of Late, Could Stage a Technical Rally Into Year-End

Small improvements are poking through in the social media giant's charts.